C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis by Roger, Simon D. et al.
Nephrol Dial Transplant (2011) 26: 3980–3986
doi: 10.1093/ndt/gfr160
Advance Access publication 19 April 2011
C.E.R.A. once every 4 weeks corrects anaemia and maintains
haemoglobin in patients with chronic kidney disease not on dialysis
Simon D. Roger
1, Francesco Locatelli
2, Rainer P. Woitas
3, Maurice Laville
4, Sheldon W. Tobe
5,
Robert Provenzano
6, Thomas A. Golper
7, Prajej Ruangkanchanasetr
8, Ho Yung Lee
9, Kwan-Dun Wu
10,
Michal Nowicki
11, Agnes Ladanyi
12, Alberto Martı ´nez-Castelao
13, Ulrich Beyer
14 and
Frank C. Dougherty
14
1Department of Renal Medicine, Gosford Hospital, Gosford, Australia,
2Department of Nephrology, Dialysis and Renal Transplant,
Alessandro Manzoni Hospital, Lecco, Italy,
3Department of Internal Medicine I, University of Bonn, Bonn, Germany,
4Department of
Nephrology, Edouard Herriot Hospital, University of Lyon, Lyon, France,
5Department of Medicine, Sunnybrook Health Science
Centre, University of Toronto, Ontario, Canada,
6Division of Nephrology, St John Hospital, Detroit, MI, USA,
7Vanderbilt University
Medical Center, Nashville, TN, USA,
8Division of Nephrology, Phramongkutklao Hospital, Bangkok, Thailand,
9Department of
Internal Medicine, Yonsei University College of Medicine, Seoul, Korea,
10Division of Nephrology, Department of Internal Medicine,
National Taiwan University Hospital, Taipei, Taiwan,
11Department of Nephrology, Hypertension and Kidney Transplantation,
Medical University of qo ´dz ´, qo ´dz ´, Poland,
12Department of Internal Medicine, Pe ´terfy Hospital, Budapest, Hungary,
13Bellvitge
University Hospital, Hospitalet, IDIBELL, Barcelona, Spain and
14F. Hoffmann-La Roche, Basel, Switzerland
Correspondence and offprint requests to: Simon D. Roger; E-mail: sroger@nsccahs.health.nsw.gov.au
Abstract
Background. No previous randomized controlled studies
have been reported examining de novo, once every 4 weeks
(Q4W) administration of erythropoiesis-stimulating agents in
chronickidneydisease(CKD)patients.Wereportresultsfrom
a randomized multinational study that compared continuous
erythropoietin receptor activator (C.E.R.A.) Q4W with darbe-
poetinalfaonceweekly(QW)orevery2weeks(Q2W)forthe
correction of anaemia in non-dialysis CKD patients.
Methods. Patients were randomized (1:1) to receive either
1.2 lg/kg C.E.R.A. Q4W or darbepoetin alfa QW/Q2W
during a 20-week correction period and an 8-week
evaluation period. Two primary end points were assessed:
the haemoglobin (Hb) response rate and the change in
average Hb concentration between baseline and evaluation.
Results. The Hb response rate for C.E.R.A. was 94.1%,
signiﬁcantly higher than the protocol-speciﬁed 60%
response rate [95% conﬁdence interval (CI): 89.1, 97.3;
P < 0.0001] and comparable with darbepoetin alfa
(93.5%; 95% CI: 88.4, 96.8; P < 0.0001). C.E.R.A. Q4W
wasnon-inferiortodarbepoetinalfaQW/Q2W,withsimilar
meanHbchangesfrombaselineof1.62g/dLand1.66g/dL,
respectively. Patients receiving C.E.R.A. showed a steady
rise in Hb, with fewer patients above the target range during
the ﬁrst 8 weeks compared with darbepoetin alfa [39 pa-
tients (25.8%) versus 72 patients (47.7%); P < 0.0001].
Adverseeventrateswerecomparablebetweenthetreatment
groups.
Conclusion. C.E.R.A. Q4W successfully corrects anaemia
and maintains stable Hb levels within the recommended
target range in non-dialysis CKD patients.
Keywords: anaemia; C.E.R.A.; chronic kidney disease; darbepoetin alfa;
haemoglobin
Introduction
The development of erythropoiesis-stimulating agents
(ESAs) has been beneﬁcial in treating the anaemia
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haemoglobin (Hb) levels, so reducing the need for blood
transfusions and improving quality of life [1, 2]. Improve-
ments in anaemia management have been the subject of
clinical trials with new agents and treatment regimens
which attempt to demonstrate potential advantages to
patients and health care providers without compromising
efﬁcacy or safety, particularly in regard to Hb levels and Hb
increase over time. An ideal agent would provide a smooth
correction in Hb levels and then maintain Hb within the
target range at a reduced dose frequency.
Methoxy polyethylene glycol-epoetin beta (MIRCERA
 ;
F.Hoffmann-La Roche, Basel, Switzerland) isa continuous
erythropoietinreceptoractivator(C.E.R.A.)withpharmaco-
logical properties distinct from other currently available
ESAs[3–6].TheefﬁcacyofC.E.R.A.incorrectinganaemia
[as therapy every 2 weeks (Q2W)] and maintaining Hb
levels [as therapy every 4 weeks (Q4W)] has been
established in a series of trials, with data from the extension
phase of the administration of C.E.R.A. in CKD patients to
treatanaemiawitha Q2W schedule (ARCTOS)studydem-
onstrating that C.E.R.A. Q4W maintained stable Hb levels
within the recommended range for up to 52 weeks in CKD
patientsnotondialysis,withefﬁcacyandsafetycomparable
with that of darbepoetin alfa administered once weekly
(QW) or Q2W [7, 8].
The correction of renal anaemia in CKD patients with
subcutaneous therapy (CORDATUS) study is the ﬁrst
randomized study to compare the efﬁcacy and safety of
de novo C.E.R.A. Q4W and darbepoetin alfa QW or
Q2W for the correction of anaemia in ESA-naive patients
with CKD not on dialysis.
Materials and methods
Study participants
The CORDATUS study was an open-label, randomized, controlled,
multicentre, parallel-group study in patients with CKD not on dialysis.
ESA-naive adults ( 18 years) with CKD Stage 3 or 4 and an estimated
glomerular ﬁltration rate of 15–59 mL/min/1.73 m
2, with a baseline Hb
concentration <10.5 g/dL and adequate iron status deﬁned as serum
ferritin  100 lg/L or transferrin saturation (TSAT)  20% or <10%
hypochromic red blood cells (RBCs), were screened for up to 2 weeks
before being randomized into two treatment groups. Exclusion criteria
included previous treatment with any ESA within 12 weeks before the
screening period, overt gastrointestinal bleeding or RBC transfusions
within 8 weeks before or during screening, a non-renal cause of anae-
mia, likelihood of early withdrawal or life expectancy of <12 months.
The study was approved by local ethics committees and carried out
according to the Declaration of Helsinki and local regulations. All patients
provided written, informed consent before the start of the study.
Procedures
Eligible patients were randomized (1:1) following the screening period to
r e c e i v eas t a r t i n gd o s eo f1 . 2lg/kg subcutaneous C.E.R.A. Q4W or darbe-
poetin alfa according to product labelling speciﬁcations (e.g. 0.45 lg/kg QW
or 0.75 lg/kg Q2W), over a 20-week correction period, followed by an
8-week evaluation period (Figure 1). Patients randomized to the darbepoetin
alfa group were treated at the QW or Q2W interval at the investigator’s
discretion.
The C.E.R.A. dose was adjusted by ~25% during the correction phase
until the response level (an Hb increase of  1 g/dL above the baseline and
at a value  10 g/dL) was reached. Subsequent to anaemia correction, the
Hb levels were to be maintained within 1 g/dL of the response Hb value
and in the range of 10–12 g/dL by implementing a ~25% dose increase or
decrease. If Hb levels exceeded 12 g/dL, treatment was temporarily inter-
rupted in both treatment arms. When Hb levels fell <12 g/dL, treatment
with C.E.R.A. was restarted at a dose ~25% below that previously
administered. Darbepoetin alfa treatment was adjusted according to ap-
proved labelling and to achieve the same Hb targets. Dosing intervals
remained unchanged throughout the study, and dose adjustments were
made during scheduled visits, no more frequently than Q4W and were
based on the most current Hb value measured within 9 days prior to the
planned dose administration.
In cases of iron deﬁciency (serum ferritin <100 lg/L, TSAT <20% or
hypochromic RBCs  10%), the protocol speciﬁed that iron supplementa-
tion should be administered orally or intravenously during the screening
and treatment periods according to centre practice and should
be discontinued in patients who had serum ferritin levels>800 lg/L or
TSAT >50%.
Study outcomes
The two primary end points of this study were the response rate until the
end of the evaluation period and the group difference in the mean change
in Hb concentration between the baseline and evaluation periods.
The secondary end points of this study were: the changes in Hb values
overtime; thetime toHbresponseassessedby Kaplan–Meier methods; the
percentage of patients with at least one Hb value>12 g/dL in the ﬁrst 8
Fig. 1. Study design.
C.E.R.A. Q4W corrects anaemia in non-dialysis CKD patients 3981weeks of the study; the proportion of patients who achieved a stable
response; the total number of dose adjustments associated with stable
response and the incidence of RBC transfusions.
Assessments
All patients were scheduled for assessments Q2W. Hb concentrations and
vital signs were measured at each study visit, while samples for iron
parameters, proteinuria, intact parathyroid hormone and a panel of stand-
ard laboratory parameters were collected ﬁve times during the 28-week
study. Serum creatinine and C-reactive protein levels were determined
four times during the study. Anti-erythropoietin antibody testing was car-
ried out at baseline, Week 17 and the ﬁnal visit. Iron administration and
RBC transfusions were recorded throughout the study, as were adverse
events (AEs).
Statistical analyses
The ﬁrst primary efﬁcacy end point evaluated Hb response rate, deﬁned as
an increase in Hb  1 g/dL compared with baseline and an Hb concen-
tration  10 g/dL. The Clopper–Pearson conﬁdence limits were used for
analysis of response to demonstrate that the lower limit of the
conﬁdence interval (CI) was >60%. Baseline Hb concentration was esti-
mated by a time-adjusted mean of all values recorded between the day the
ﬁrst study dose was administered and the previous 20 days. The Hb value
on the day of the ﬁrst dose was included in the baseline calculation, as this
assessment was performed before administration of the ﬁrst dose. To
correct for any increase in Hb caused by RBC transfusions, values meas-
ured within 3 weeks after a transfusion were replaced by the Hb value
measured immediately before the transfusion.
The second primary efﬁcacy end point evaluated the group difference
in the mean change in Hb levels between the baseline and evaluation
periods (Weeks 21–29). Using an analysis of covariance by treatment,
a two-sided 95% CI was calculated for the mean difference between
groups, and treatment with C.E.R.A. was regarded as non-inferior to
treatment with darbepoetin alfa if the lower limit of the CI was greater
than  0.75 g/dL, with a t-test used to calculate the P-value.
To detect both primary end points with 90% power in all analysis
populations [the intent-to-treat (ITT) and per protocol populations], 150
patients were required. For the analysis of response, at least 126 patients
were required in each arm to demonstrate a response rate of  60% with a
90% power, assuming a true response rate of 75%. For the non-inferiority
test, 105 patients per arm were required to show that the lower limit of the
95% CI was greater than  0.75 g/dL, on the assumption of 90% power, a
two-sided signiﬁcance level of 5% and a true difference of no >0.3 g/dL
between the two arms.
The safety population included all randomized patients who received at
least one dose of C.E.R.A. or darbepoetin alfa. Group summary statistics
were recorded for all safety parameters. Frequencies and incidence rates of
AEs were tabulated by treatment group and calculated on a per patient
basis. All vital sign measurements and laboratory data were assessed for
clinically relevant abnormalities and any changes from baseline.
Results
Study population
A total of 420 patients from 64 centres in 16 countries
were screened, of whom 307 were randomized into two
treatment groups (153 patients to C.E.R.A. and 154
patients to darbepoetin alfa, 60 at the QW interval and 94
at the Q2W interval) (Figure 2). Of these, 305 patients
Fig. 2. Patient disposition.
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patients in the C.E.R.A. group were randomized but did
not receive study medication as consent was withdrawn
before the ﬁrst dose of the study drug was administered.
One other patient assigned to C.E.R.A. was administered
darbepoetin alfa in error and maintained this treatment
throughout the study. Twenty-nine patients withdrew from
the study; 12 (8%) in the C.E.R.A. arm and 17 (11%) in the
darbepoetin alfa arm. Six patients (4%) in the C.E.R.A.
group and nine patients (6%) in the darbepoetin alfa group
withdrew for safety reasons. In each treatment group, two
patients withdrew due to an AE. In the C.E.R.A. group, one
patient reported ulcerative keratitis and one patient reported
pregnancy. In the darbepoetin alfa group, one patient re-
ported recurrent lymphocytic leukaemia and one patient
reported metastatic renal cancer. Eleven patients ceased
participation in the study due to death; four in the
C.E.R.A. group and seven in the darbepoetin alfa group.
Fourteen patients withdrew due to non-safety-related
reasons, which included refusal of treatment, lack of
co-operation and withdrawal of consent.
Patient baseline characteristics and risk factors
for vascular events and haemorrhage were well balanced
across both treatment groups (Table 1). The most
frequent aetiologies of CKD in patients receiving
C.E.R.A. or darbepoetin alfa in this study were: diabetes
(46 and 45%), hypertension/large vessel disease (49 and
41%), glomerulonephritis (12 and 10%) and interstitial
nephritis/pyelonephritis (13 and 8%). Multiple attributions
were possible.
Efﬁcacy
The Hb response rate for C.E.R.A. was statistically signiﬁ-
cant >60% in the ITT population, and rates were compa-
rable between C.E.R.A. and darbepoetin alfa: 144/153
responders [94.1% (95% CI: 89.1, 97.3)] versus 144/154
responders [93.5% (95% CI: 88.4, 96.8)]. Similar
ﬁndings were observed in the per protocol population,
conﬁrming results from the ITT population (Figure 3).
The second primary end point analysis demonstrated
a between-group treatment difference of  0.036 g/dL
(1.62 g/dL in the C.E.R.A. arm versus 1.66 g/dL in the
darbepoetin alfa arm) in Hb change from baseline to eval-
uation period in the ITT population. The lower limit of the
95% CI for the group difference was  0.25 g/dL, which
was above the protocol-speciﬁed non-inferiority limit of
Table 1. Baseline patient characteristics and risk factors
a
C.E.R.A.,
n ¼ 153
Darbepoetin
alfa, n ¼ 154
Male, n (%) 67 (44) 67 (44)
Race, n (%)
Caucasian 92 (60) 97 (63)
Oriental 61 (40) 57 (37)
Mean (SD) age, year 65.4 (14.3) 67.4 (13.4)
Mean (SD) weight, kg 69.6 (15.3) 70.0 (16.8)
Mean (SD) Hb, g/dL 9.53 (0.74) 9.53 (0.65)
Mean (SD) GFR,
mL/min/1.73 m
2
27.5 (14.1) 27.1 (12.8)
Median (IQR) ferritin, lg/L 186 (118–331) 207 (130–336)
Median (IQR) TSAT, % 24.0 (19.0–31.5) 23.8 (18.3–30.4)
Risk factors for vascular
events and haemorrhage, n (%)
Arterial hypertension 150 (98) 147 (95)
Hyperlipidaemia 106 (69) 107 (69)
Diabetes 86 (56) 81 (53)
Ischaemic heart disease 43 (28) 48 (31)
Congestive heart failure 25 (16) 23 (15)
aGFR, glomerular ﬁltration rate; IQR, interquartile range.
Fig. 3. Hb response rate in the ITT and per protocol populations.
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inferior to darbepoetin alfa (P < 0.0001). Analysis in the
per protocol population conﬁrmed these results.
Analysis of the secondary end points of the
study showed that the patients treated with C.E.R.A. had
a controlled rise in Hb concentrations (Figure 4), with a
mean increase of 0.20 g/dL/week during the initial 8 weeks
of the study compared with 0.27 g/dL/week for patients in
the darbepoetin alfa group. The median time to Hb re-
sponse was 43 days in the C.E.R.A. group and 29 days
in the darbepoetin alfa group, reﬂecting the more gradual
increase in Hb concentrations associated with C.E.R.A.
Fewer patients treated with C.E.R.A. had Hb values ex-
ceeding 12 g/dL in the ﬁrst 8 weeks of treatment compared
with those receiving darbepoetin alfa [39 patients (25.8%)
versus 72 patients (47.7%), respectively; P < 0.0001]
(Figure 5).
Stable response (deﬁned as  75% of the scheduled Hb
values within the range 10–12 and  1 g/dL from baseline
for any 8-week time period, regardless of the requirement
for dose adjustment) was found in 105 patients (68.6%)
treated with C.E.R.A. compared with 112 patients
(72.7%) treated with darbepoetin alfa (not signiﬁcant).
The total number of patients requiring any dose change
Fig. 4. Hb increase over time in the ITT population.
Fig. 5. Percentage of patients with Hb levels >12 g/dL.
Fig. 6. Comparison of median equivalent 4-week study drug dose
over time.
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similar in the C.E.R.A. and darbepoetin alfa treatment
groups [65 patients (61.9%) versus 64 patients (57.1%);
not signiﬁcant]. The mean number of dose changes per
patient associated with stable response was very similar
between treatment groups (1.12 for C.E.R.A. and 1.10 for
darbepoetin alfa). Multiple dose adjustments ( 5 adjust-
ments) were required by fewer patients treated with
C.E.R.A. compared with those receiving darbepoetin alfa
during the study (10.7 versus 21.3%, respectively). Corre-
spondingly, the change in median dose from baseline to
evaluation with C.E.R.A. was very small compared with
the dose change in patients treated with darbepoetin alfa
(6.6 versus 35.6%, respectively) (Figure 6).
Ten patients (6.5%) in the darbepoetin alfa group
received one or more transfusions compared with ﬁve
patients (3.3%) in the C.E.R.A. group (not signiﬁcant).
Reasons given for transfusions were similar in the two
treatment groups. Patients in the C.E.R.A. treatment arm
received RBC transfusions in association with anaemia
of unknown aetiology, renal neoplasm, surgery for
intestinal perforation and concurrent infections or inﬂam-
mations. Patients in the darbepoetin alfa treatment arm
received RBC transfusions associated with anaemia of un-
known aetiology, haemorrhage, infections, surgery, renal
neoplasm, anaemia of malignant disease and acute cardiac
failure.
Safety
Of 307 patients randomized, 305 received at least one dose
of the study medication (150 patients in the C.E.R.A. arm
and 155 patients in the darbepoetin alfa arm). In general,
both treatments were well tolerated. Most AEs experienced
by patients in each study arm were reported to be mild to
moderate in intensity, and rates were comparable between
the two groups. One hundred and nine patients (72.7%) in
the C.E.R.A. arm experienced AEs compared with 123
patients (79.4%) in the darbepoetin alfa arm; this difference
was not statistically signiﬁcant. The most frequently
reported AEs in the study for C.E.R.A. and darbepoetin
alfa were hypertension (16.0 versus 23.9%), renal impair-
ment (6.0 versus 10.3%), hyperkalaemia (8.7 versus 5.2%),
upper respiratory tract infection (6.0 versus 7.1%) and
constipation (3.3 versus 7.7%) (Table 2). Ten patients
(6.7%) in the C.E.R.A. group and 17 patients (11.0%) in
the darbepoetin alfa group experienced at least one AE that
was assessed as treatment related by the investigator. Of
these, the most common AE was hypertension, experienced
by 4.7% of patients treated with C.E.R.A. and 10.3% of
patients treated with darbepoetin alfa.
Numerically, more patients in the darbepoetin alfa arm
experienced serious AEs compared with patients in the
C.E.R.A. arm (12 versus 6%, respectively). No patient
had a serious AE that was judged to be treatment related.
Eleven deaths [four patients (3%) in the C.E.R.A. group
and seven patients (5%) in the darbepoetin alfa group] were
reported during the study, none of which was considered to
be related to the treatment. No single cause of death was
reported in more than one case in either treatment arm. No
antibodies to study drugs were detected.
Discussion
Approximately 50% of CKD patients not on dialysis are
anaemic [9]. Treatment with short-acting ESAs in this
population may require frequent dosing via subcutaneous
injections, which can affect patient compliance. The
extended dosing interval associated with C.E.R.A. reduces
the number of injections, while decreased injection site
pain has been demonstrated in healthy subjects [10]. All
of these characteristics may help to improve anaemia man-
agement in this population.
This study demonstrates that C.E.R.A. Q4W adminis-
tered subcutaneously was as effective as darbepoetin alfa
given more frequently in the correction of anaemia in ESA-
naive patients with CKD not on dialysis. Both primary end
points of the study were met, as patients in the C.E.R.A.
Q4W arm exhibited a 94.1% response rate and statistically
veriﬁed non-inferiority to darbepoetin alfa in Hb change
over time. Patients in the C.E.R.A. Q4W group exhibited
a steady increase in Hb concentrations, with a median time
to response of 43 days. As a result of the slower Hb in-
crease, fewer patients in the C.E.R.A. Q4W group had Hb
values that exceeded 12 g/dL, the upper limit of the target
range, while median C.E.R.A. doses changed very slightly
over time and fewer patients receiving C.E.R.A. required
multiple dose adjustments. It is possible that these differ-
ences result from the starting dose of darbepoetin alfa
speciﬁed by the approved prescribing information.
Nonetheless, the slight change in the C.E.R.A. dose and
the limited requirement for dose adjustment over the 28-
week study period suggest that the starting dose of 1.2 lg/
kg/Q4W is appropriate in this clinical setting. However, the
initial dosing of darbepoetin alfa to correct anaemia may
need to be revised in the current more conservative climate
of anaemia management.
C.E.R.A. was well tolerated; the most common AEs
reported in both treatment groups were characteristic of
the population under study and included hypertension,
renal impairment, hyperkalaemia, upper respiratory tract
infection and constipation. The safety data from this study
conﬁrmed the results from a recently published pooled
analysis investigating the safety proﬁle of C.E.R.A. com-
pared with other ESAs in patients with CKD [11].
The results from this study add to published data from
the C.E.R.A. phase III studies, which have shown that
C.E.R.A. Q4W can effectively maintain Hb levels within
Table 2. Frequently reported AEs (>5% in either group)
C.E.R.A.,
n ¼ 150 (%)
Darbepoetin alfa,
n ¼ 155 (%)
Hypertension 24 (16.0) 37 (23.9)
Renal impairment 9 (6.0) 16 (10.3)
Hyperkalaemia 13 (8.7) 8 (5.2)
Upper respiratory tract infection 9 (6.0) 11 (7.1)
Constipation 5 (3.3) 12 (7.7)
Diarrhoea 10 (6.7) 6 (3.9)
Urinary tract infection 6 (4.0) 8 (5.2)
Hypotension 5 (3.3) 8 (5.2)
Nasopharyngitis 5 (3.3) 8 (5.2)
Pneumonia 2 (1.3) 8 (5.2)
C.E.R.A. Q4W corrects anaemia in non-dialysis CKD patients 3985the target range in CKD patients on dialysis and those not
on dialysis without compromising efﬁcacy or safety [7, 12,
13]. Another large, randomized study has shown that sig-
niﬁcantly more dialysis patients treated with once-monthly
C.E.R.A. maintained Hb levels within the target range than
those treated with darbepoetin alfa at the same dosing in-
terval [14]. The data from the current study support the use
of C.E.R.A. Q4W to correct anaemia and then maintain Hb
levels in patients with CKD not on dialysis through a
simpliﬁed, convenient and practical dosing regimen with
beneﬁts for both patients and healthcare providers. These
studies demonstrate that C.E.R.A. is the only ESA proven
to manage anaemia with a Q4W schedule in patients with
all stages of CKD.
In conclusion, the CORDATUS study is the ﬁrst clinical
trial to prove that C.E.R.A. Q4W successfully corrects
anaemia in CKD patients not on dialysis, with fewer dose
changes and with a safety proﬁle comparable to that of
darbepoetin alfa administered according to approved
labelling.
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